GGrantIndex
← Leaderboards

John E. Shively

City Of Hope National Medical Center

$5,985,042
Attributed
$9,182,047
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY200625
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,182,047 · 11

By mechanism

R01$8,815,995 · 4
M01$209,555 · 6
P01$156,497 · 1

Top collaborators

Most similar at City Of Hope National Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsMalignant NeoplasmsResponseCancer CellAntibodiesImmuneMcf7 CellRegimenImageProteinsTumorT-LymphocyteToxic EffectDoseIn VivoBaseResistanceClinicClinically RelevantFda ApprovedPre-ClinicalCarcinoembryonic AntigenEnvironmentBreast

Grant awards (28)

Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia$738,698
R01 · FY2025 · CA
Targeted radiation and immunocytokine therapy for CEA positive malignancies$676,263
R01 · FY2025 · CA · contact PI
Targeted radiation and immunocytokine therapy for CEA positive malignancies$642,450
R01 · FY2024 · CA · contact PI
Targeted radiation and immunocytokine therapy for CEA positive malignancies$676,263
R01 · FY2023 · CA · contact PI
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2023 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2022 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2021 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2020 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2019 · CA
Role of CEACAM1 in Epithelial Cell Polarization$424,730
R01 · FY2010 · CA · contact PI
Role of CEACAM1 in Epithelial Cell Polarization$416,403
R01 · FY2009 · CA · contact PI
IMMUNOLOGICAL AND GENETIC ANALYSIS OF AUTOINFLAMMATORY GENES IN FIBROMYALGIA$53,335
M01 · FY2009 · RR · contact PI
Role of CEACAM1 in Epithelial Cell Polarization$404,273
R01 · FY2008 · CA · contact PI
IMMUNOLOGICAL AND GENETIC ANALYSIS OF AUTOINFLAMMATORY GENES IN FIBROMYALGIA$60,088
M01 · FY2008 · RR · contact PI
Role of CEACAM1 in Epithelial Cell Polarization$400,270
R01 · FY2007 · CA · contact PI
IMMUNOLOGICAL AND GENETIC ANALYSIS OF AUTOINFLAMMATORY GENES IN FIBROMYALGIA$57,179
M01 · FY2007 · RR · contact PI
OPTICAL BIOSENSOR FOR THE EARLY DETECTION OF BREAST CANCER$1,939
M01 · FY2007 · RR · contact PI
Role of CEACAM1 in Epithelial Cell Polarization$400,219
R01 · FY2006 · CA · contact PI
IMMUNOLOGICAL AND GENETIC ANALYSIS OF AUTOINFLAMMATORY GENES IN FIBROMYALGIA$30,482
M01 · FY2006 · RR · contact PI
OPTICAL BIOSENSOR FOR THE EARLY DETECTION OF BREAST CANCER$6,532
M01 · FY2006 · RR · contact PI
ROLE OF BGP IN BREAST EPITHELIAL CELL POLARIZATION$422,886
R01 · FY2004 · CA
ROLE OF BGP IN BREAST EPITHELIAL CELL POLARIZATION$411,518
R01 · FY2003 · CA
ROLE OF BGP IN BREAST EPITHELIAL CELL POLARIZATION$399,534
R01 · FY2002 · CA
Radioimmunoconjugates$0
P01 · FY2002 · CA
ROLE OF BGP IN BREAST EPITHELIAL CELL POLARIZATION$387,898
R01 · FY2001 · CA
ANTIBODY CHELATES AND CONJUGATES$0
P01 · FY2001 · CA
ROLE OF BGP IN BREAST EPITHELIAL CELL POLARIZATION$417,694
R01 · FY2000 · CA
ANTIBODY CHELATES AND CONJUGATES$156,497
P01 · FY2000 · CA